Source:http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/1552
| Predicate | Object |
|---|---|
| rdf:type | |
| rdfs:label |
K-TAB (Tablet, Film Coated, Extended Release)
|
| dailymed-instance:dosage |
The usual dietary potassium intake by the average
adult is 50 to 100 mEq per day. Potassium depletion sufficient to cause hypokalemia
usually requires the loss of 200 or more mEq of potassium from the total body
store. Dosage must be adjusted to the individual
needs of each patient. The dose for the prevention of hypokalemia is typically
in the range of 20 mEq per day. Doses of 40-100 mEq per day or more
are used for the treatment of potassium depletion. Dosage should be
divided if more than 20 mEq per day is given such that no more than 20 mEqis given in a single dose. K-TAB tablets provide
10 mEq of potassium chloride. K-TAB tablets should
be taken with meals and with a glass of water or other liquid. This product
should not be taken on an empty stomach because of its potential for gastric
irritation (see WARNINGS). NOTE:K-TAB tablets are
to be swallowed whole without crushing, chewing or sucking the tablets.
|
| dailymed-instance:descripti... |
K-TAB (potassium chloride extended-release tablets)
is a solid oral dosage form of potassium chloride containing 750 mg of potassium
chloride, USP, equivalent to 10 mEq of potassium in a film-coated (not enteric-coated),
wax matrix tablet. This formulation is intended to slow the release of potassium
so that the likelihood of a high localized concentration of potassium chloride
within the gastrointestinal tract is reduced. The expended inert, porous,
wax/polymer matrix is not absorbed and may be excreted intact in the stool. K-TAB tablets are an electrolyte replenisher. The chemical
name is potassium chloride, and the structural formula is KCl. Potassium
chloride, USP, occurs as a white, granular powder or as colorless crystals.
It is odorless and has a saline taste. Its solutions are neutral to litmus.
It is freely soluble in water and insoluble in alcohol.<br/>Inactive Ingredients: Castor oil, cellulosic polymers, colloidal silicon
dioxide, D&C Yellow No. 10, magnesium stearate, paraffin, polyvinyl acetate,
titanium dioxide, vanillin and vitamin E.
|
| dailymed-instance:clinicalP... |
Potassium ion is the principal intracellular cation
of most body tissues. Potassium ions participate in a number of essential
physiological processes including the maintenance of intracellular tonicity,
the transmission of nerve impulses, the contraction of cardiac, skeletal and
smooth muscle, and the maintenance of normal renal function. The intracellular concentration of potassium is approximately
150 to 160 mEq per liter. The normal adult plasma concentration is 3.5 to
5 mEq per liter. An active ion transport system maintains this gradient across
the plasma membrane. Potassium is a normal dietary
constituent and under steady state conditions the amount of potassium absorbed
from the gastrointestinal tract is equal to the amount excreted in the urine.
The usual dietary intake of potassium is 50 to 100 mEq per day. Potassium depletion will occur whenever the rate of potassium
loss through renal excretion and/or loss from the gastrointestinal tract exceeds
the rate of potassium intake. Such depletion usually develops as a consequence
of therapy with diuretics, primary or secondary hyperaldosteronism, diabetic
ketoacidosis, or inadequate replacement of potassium in patients on prolonged
parenteral nutrition. Depletion can develop rapidly with severe diarrhea,
especially if associated with vomiting. Potassium depletion due to these
causes is usually accompanied by a concomitant loss of chloride and is manifested
by hypokalemia and metabolic alkalosis. Potassium depletion may produce weakness,
fatigue, disturbances of cardiac rhythm (primarily ectopic beats), prominent
U-waves in the electrocardiogram, and, in advanced cases, flaccid paralysis
and/or impaired ability to concentrate urine. If
potassium depletion associated with metabolic alkalosis cannot be managed
by correcting the fundamental cause of the deficiency, e.g., where the patient
requires long term diuretic therapy, supplemental potassium in the form of
high potassium food or potassium chloride may restore normal potassium levels. In rare circumstances, (e.g., patients with renal tubular
acidosis) potassium depletion may be associated with metabolic acidosis and
hyperchloremia. In such patients potassium replacement should be accomplished
with potassium salts other than the chloride, such as potassium bicarbonate,
potassium citrate, potassium acetate, or potassium gluconate.
|
| dailymed-instance:activeIng... | |
| dailymed-instance:contraind... |
Potassium supplements are contraindicated in patients
with hyperkalemia since a further increase in serum potassium concentration
in such patients can produce cardiac arrest. Hyperkalemia may complicate
any of the following conditions: chronic renal failure, systemic acidosis
such as diabetic acidosis, acute dehydration, extensive tissue breakdown as
in severe burns, adrenal insufficiency, or the administration of a potassium-sparing
diuretic, e.g., spironolactone, triamterene, or amiloride (see OVERDOSAGE ). K-TAB tablets are contraindicated
in patients with known hypersensitivity to any ingredient in this product. Controlled-release formulations of potassium chloride have
produced esophageal ulceration in certain cardiac patients with esophageal
compression due to an enlarged left atrium. Potassium supplementation, when
indicated in such patients, should be given as a liquid preparation. All solid oral dosage forms of potassium chloride are contraindicated
in any patient in whom there is structural, pathological, e.g., diabetic gastroparesis,
or pharmacologic (use of anticholinergic agents or other agents with anticholinergic
properties at sufficient doses to exert anticholinergic effects) cause for
arrest or delay in tablet passage through the gastrointestinal tract.
|
| dailymed-instance:supply |
K-TAB (potassium chloride extended-release tablets,
USP) contains 750 mg of potassium chloride (equivalent to 10 mEq). K-TAB
tablets are provided as yellow, ovaloid, extended-release Filmtab tablets
in bottles of 100 (NDC 0074-7804-13),
1000 (NDC 0074-7804-19) and 5000 (NDC 0074-7804-59) and in ABBO-PAC unit
dose packages of 100 (NDC 0074-7804-11).<br/>Recommended Storage: Store below 86��F (30��C).
|
| dailymed-instance:genericDr... | |
| dailymed-instance:activeMoi... | |
| dailymed-instance:inactiveI... |
dailymed-ingredient:Castor_oil,
dailymed-ingredient:D&C_Yellow_No._10,
dailymed-ingredient:cellulosic_polymers,
dailymed-ingredient:colloidal_silicon_dioxide,
dailymed-ingredient:magnesium_stearate,
dailymed-ingredient:paraffin,
dailymed-ingredient:polyvinyl_acetate,
dailymed-ingredient:titanium_dioxide,
dailymed-ingredient:vanillin,
dailymed-ingredient:vitamin_E
|
| dailymed-instance:possibleD... | |
| dailymed-instance:overdosag... |
The administration of oral potassium salts to persons
with normal excretory mechanisms for potassium rarely causes serious hyperkalemia.
However, if excretory mechanisms are impaired or if intravenous administration
is too rapid, potentially fatal hyperkalemia can result (see CONTRAINDICATIONS and WARNINGS). It is important
to recognize that hyperkalemia is usually asymptomatic and may be manifested
only by an increased serum potassium concentration (6.5-8.0 mEq/L) and characteristic
electrocardiographic changes (peaking of T-waves, loss P-waves, depression
of S-T segments, and prolongation of the QT intervals). Late manifestations
include muscle paralysis and cardiovascular collapse from cardiac arrest (9-12
mEq/L). Treatment measures for hyperkalemia include
the following: In treating hyperkalemia, it should be recalled that
in patients who have been stabilized on digitalis, lowering the serum potassium
concentration too rapidly can produce digitalis toxicity. The extended release feature means that absorption and toxic
effects may be delayed for hours. Consider standard measures to remove any
unabsorbed drug.
|
| dailymed-instance:genericMe... |
potassium chloride
|
| dailymed-instance:fullName |
K-TAB (Tablet, Film Coated, Extended Release)
|
| dailymed-instance:adverseRe... |
One of the most severe adverse effects is hyperkalemia
(see CONTRAINDICATIONS, WARNINGS , and OVERDOSAGE). There also
have been reports of upper and lower gastrointestinal conditions including
obstruction, bleeding, ulceration, and perforation (see CONTRAINDICATIONSand WARNINGS). The most common adverse reactions to oral potassium salts
are nausea, vomiting, flatulence, abdominal pain/discomfort, and diarrhea.
These symptoms are due to irritation of the gastrointestinal tract and are
best managed by taking the dose with meals, or reducing the amount taken at
one time. Skin rash has been reported rarely.
|
| dailymed-instance:indicatio... |
BECAUSE OF REPORTS OF INTESTINAL
AND GASTRIC ULCERATION AND BLEEDING WITH CONTROLLED-RELEASE POTASSIUM CHLORIDE
PREPARATIONS, THESE DRUGS SHOULD BE RESERVED FOR THOSE PATIENTS WHO CANNOT
TOLERATE OR REFUSE TO TAKE LIQUID OR EFFERVESCENT POTASSIUM PREPARATIONS,
OR FOR PATIENTS WITH WHOM THERE IS A PROBLEM OF COMPLIANCE WITH THESE PREPARATIONS. The use of potassium salts in patients receiving
diuretics for uncomplicated essential hypertension is often unnecessary when
such patients have a normal dietary pattern, and when low doses of the diuretic
are used. Serum potassium should be checked periodically, however, and, if
hypokalemia occurs, dietary supplementation with potassium-containing foods
may be adequate to control milder cases. In more severe cases and if dose
adjustment of the diuretic is ineffective or unwarranted supplementation with
potassium salts may be indicated.
|
| dailymed-instance:represent... | |
| dailymed-instance:routeOfAd... | |
| dailymed-instance:name |
K-TAB
|